HCN4
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
As of the edition of 20 October 2026, HCN4 (potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, UniProt Q9Y3Q4) has 3 drugs tested at it and 6 companies on the list, 0 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y3Q4
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Heart and blood vessels; Infections; Blood and lymph; Cancer; Lungs and airways; Immune system; Inherited and neonatal; Nervous system
- Registered trials of its drugs
- 92
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ivabradine | Marketed | Phase 4 | Ends 2026 |
| Dronedarone | Marketed | Phase 4 | none listed |
| Mosedipimod | Active | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 4 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 6 |
The other 3 companies at HCN4
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at HCN4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.